Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Permacol Use in Infected Fields

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have given written Informed Consent~* Be 18-85 years of age (inclusive)~* Have prosthetic mesh that is in proximity to an infected wound that has failed conservative management for at least 3 months, with mesh exposure and a draining wound, or that is in proximity to an abscess that requires operative intervention.~* Have a wound characterized by purulent discharge, positive gram stain or positive culture to document infection~* Be a candidate for surgical removal of infected mesh placed for repair of ventral/incisional hernias and concomitant abdominal wall reconstruction~* Have an ASA Score ≤3~* Have a body mass index (BMI) between 16.5 and 40 inclusive~* Be a candidate for anticipated primary approximation of skin/wound~* Have a life expectancy of at least 18 months~* Be willing to allow biopsy of implant if secondary wound opening is performed or spontaneous implant exposure occurs~Exclusion Criteria:~* Have loss of abdominal domain such that the operation would be impractical or would adversely effect respiratory or cardiovascular function to an unacceptable degree~* Have an enterocutaneous fistula in proximity to wound/mesh~* Be a candidate for emergency surgery that would make giving valid Informed Consent impractical~* Be currently taking part in another clinical study that conflicts with the current study~* Have known allergy to porcine collagen products~* Have active generalized peritonitis or intraperitoneal sepsis~* Have active necrotizing fasciitis~* Have active abdominal compartment syndrome~* Have active untreated metabolic or systemic illness~* Report unintentional weight loss \>10% of body weight in the previous 90 days~* Have known collagen metabolism disorder.(e.g., Ehlers-Danlos syndrome)~* Have known altered immune response (e.g., HIV or other immunodeficiency disorder))~* Have chronic renal failure~* Have known active malignancy present~* Have history of systemic chemotherapy within previous 1 year~* Have lifetime history of radiation to the abdomen, pelvis or thorax~* Have inguinal or groin hernia as primary diagnosis~* Be currently pregnant or planning to become pregnant during study period~* Be unable to give valid informed consent or comply with required follow- up schedule~* Suffer from mental capacity sufficiently severe to make informed consent unobtainable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Permacol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).